Cargando…
Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes
OBJECTIVE: Complete prevention of diabetic neuropathies has not been previously demonstrated. We sought to determine whether long-term near-normoglycaemia maintained from the diagnosis of type 1 diabetes is associated with polyneuropathy and cardiac autonomic dysfunction. DESIGN: Prospective observa...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479996/ https://www.ncbi.nlm.nih.gov/pubmed/26109108 http://dx.doi.org/10.1136/bmjopen-2014-006559 |
_version_ | 1782378103010492416 |
---|---|
author | Ziegler, Dan Behler, Margarete Schroers-Teuber, Maria Roden, Michael |
author_facet | Ziegler, Dan Behler, Margarete Schroers-Teuber, Maria Roden, Michael |
author_sort | Ziegler, Dan |
collection | PubMed |
description | OBJECTIVE: Complete prevention of diabetic neuropathies has not been previously demonstrated. We sought to determine whether long-term near-normoglycaemia maintained from the diagnosis of type 1 diabetes is associated with polyneuropathy and cardiac autonomic dysfunction. DESIGN: Prospective observational study over 24 years. SETTING: Ambulatory care. PARTICIPANTS: 32 newly diagnosed patients with type 1 diabetes aged 20.3±1.0 years, duration of diabetes 2.7±0.3 weeks. INTERVENTION: Insulin therapy according to standards of care. PRIMARY AND SECONDARY OUTCOME MEASURES: Motor and sensory nerve conduction velocity (MNCV and SNCV), heart rate variability (HRV), and confirmed clinical polyneuropathy measured at 15 time points over 24 years and quantitative sensory testing (QST) determined over 20–22 years. RESULTS: 11 patients were well controlled over 24 years with mean glycated haemoglobin (HbA1c) <7.0% (6.5±0.1%; group 1), whereas 21 patients were poorly controlled (mean HbA1c ≥7.0%: 8.3±0.2%; group 2). After 24 years, MNCV was faster in group 1 versus group 2 in the median (55.5±1.6 vs 48.9±1.6 m/s), ulnar (56.5±1.5 vs 49.3±1.7 m/s) and peroneal nerve (44.7±1.6 vs 36.8±2.5 m/s), while SNCV was faster in the median (53.6±1.6 vs 45.5±2.8 m/s), ulnar (54.7±1.8 vs 43.0±3.9 m/s), and sural nerve (44.5±1.8 vs 35.5±2.6 m/s; all p<0.05). The annual decline in peroneal MNCV and sural SNCV in group 1 was sixfold and threefold faster in group 2 than in group 1, respectively. Likewise, impairment in QST and HRV developed at faster rates in group 2. After 24 years, 64% of patients in group 2, but none in group 1, developed confirmed clinical polyneuropathy. CONCLUSIONS: Near-normoglycaemia maintained from the diagnosis of type 1 diabetes over 24 years was associated with a complete prevention of the decline in hyperglycaemia-related peripheral and autonomic nerve function, and development of confirmed clinical polyneuropathy. |
format | Online Article Text |
id | pubmed-4479996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-44799962015-07-02 Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes Ziegler, Dan Behler, Margarete Schroers-Teuber, Maria Roden, Michael BMJ Open Diabetes and Endocrinology OBJECTIVE: Complete prevention of diabetic neuropathies has not been previously demonstrated. We sought to determine whether long-term near-normoglycaemia maintained from the diagnosis of type 1 diabetes is associated with polyneuropathy and cardiac autonomic dysfunction. DESIGN: Prospective observational study over 24 years. SETTING: Ambulatory care. PARTICIPANTS: 32 newly diagnosed patients with type 1 diabetes aged 20.3±1.0 years, duration of diabetes 2.7±0.3 weeks. INTERVENTION: Insulin therapy according to standards of care. PRIMARY AND SECONDARY OUTCOME MEASURES: Motor and sensory nerve conduction velocity (MNCV and SNCV), heart rate variability (HRV), and confirmed clinical polyneuropathy measured at 15 time points over 24 years and quantitative sensory testing (QST) determined over 20–22 years. RESULTS: 11 patients were well controlled over 24 years with mean glycated haemoglobin (HbA1c) <7.0% (6.5±0.1%; group 1), whereas 21 patients were poorly controlled (mean HbA1c ≥7.0%: 8.3±0.2%; group 2). After 24 years, MNCV was faster in group 1 versus group 2 in the median (55.5±1.6 vs 48.9±1.6 m/s), ulnar (56.5±1.5 vs 49.3±1.7 m/s) and peroneal nerve (44.7±1.6 vs 36.8±2.5 m/s), while SNCV was faster in the median (53.6±1.6 vs 45.5±2.8 m/s), ulnar (54.7±1.8 vs 43.0±3.9 m/s), and sural nerve (44.5±1.8 vs 35.5±2.6 m/s; all p<0.05). The annual decline in peroneal MNCV and sural SNCV in group 1 was sixfold and threefold faster in group 2 than in group 1, respectively. Likewise, impairment in QST and HRV developed at faster rates in group 2. After 24 years, 64% of patients in group 2, but none in group 1, developed confirmed clinical polyneuropathy. CONCLUSIONS: Near-normoglycaemia maintained from the diagnosis of type 1 diabetes over 24 years was associated with a complete prevention of the decline in hyperglycaemia-related peripheral and autonomic nerve function, and development of confirmed clinical polyneuropathy. BMJ Publishing Group 2015-06-24 /pmc/articles/PMC4479996/ /pubmed/26109108 http://dx.doi.org/10.1136/bmjopen-2014-006559 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Diabetes and Endocrinology Ziegler, Dan Behler, Margarete Schroers-Teuber, Maria Roden, Michael Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes |
title | Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes |
title_full | Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes |
title_fullStr | Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes |
title_full_unstemmed | Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes |
title_short | Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes |
title_sort | near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes |
topic | Diabetes and Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479996/ https://www.ncbi.nlm.nih.gov/pubmed/26109108 http://dx.doi.org/10.1136/bmjopen-2014-006559 |
work_keys_str_mv | AT zieglerdan nearnormoglycaemiaanddevelopmentofneuropathya24yearprospectivestudyfromdiagnosisoftype1diabetes AT behlermargarete nearnormoglycaemiaanddevelopmentofneuropathya24yearprospectivestudyfromdiagnosisoftype1diabetes AT schroersteubermaria nearnormoglycaemiaanddevelopmentofneuropathya24yearprospectivestudyfromdiagnosisoftype1diabetes AT rodenmichael nearnormoglycaemiaanddevelopmentofneuropathya24yearprospectivestudyfromdiagnosisoftype1diabetes |